Perrigo Q1: EPS Beat Masks Sales Decline, Cost Savings Support Margins

What happened

Perrigo's Q1 results beat EPS estimates despite a year-over-year sales miss, as cost savings from Project Energize and Supply Chain Reinvention partially offset weakness in cough/cold categories. Sales fell due to soft OTC demand and infant formula pressures, but gains in Women's Health and Infant Formula provided some offset. The company continues to execute its turnaround strategy, with adjusted EPS guidance of $2.70-$2.80 for 2025, though high leverage (~7x net debt/EBITDA) and an unresolved Irish tax dispute remain overhangs. The beat is a positive signal for margin resilience, but the top-line decline reinforces the need for sustained cost execution and category recovery to justify the discounted valuation. Overall, the quarter shows progress on costs but highlights the fragile revenue base, keeping the risk/reward balanced.

Implication

The Q1 beat provides initial evidence that cost programs can defend margins even with revenue pressure, supporting the deep value thesis if leverage trends down. However, investors should monitor if top-line pressures persist and whether the Irish tax dispute escalates, as these could impair the equity's recovery path. The setup remains compelling only for those tolerant of high leverage and execution risk.

Thesis delta

The Q1 results moderately support the base case that management can stabilize margins via cost cuts, but the persistent sales decline and reliance on cost savings rather than organic growth shift the focus from revenue recovery to margin defense. This reinforces the need for deleveraging as a key catalyst, rather than top-line expansion.